Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Theragenics’ recent rhetoric about the medical device tax captures many of the repeal movement’s high points: layoffs, restructuring and the myth of a medtech windfall contained in healthcare reform. Theragenics’ (NYSE:TGX) 1st-quarter financial report appeared to provide the company an opportunity to highlight the negative impacts of the 2.3% medical device tax that took effect at the start of the year. In discussing the Buford, Ga.-based device makers’ mixed Q1 results, CEO Christine Jacobs invoked the tax as at least partly responsible for upcoming layoffs and outsourcing and she challenged the notion that the Affordable Care Act, which the tax was designed to help fund, represents a windfall for industry.
Help employers find you! Check out all the jobs and post your resume.
